ARS Pharmaceuticals (NASDAQ:SPRY) Upgraded at Zacks Research

ARS Pharmaceuticals (NASDAQ:SPRY) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Wednesday,Zacks.com reports.

A number of other equities research analysts have also recently issued reports on SPRY. Roth Mkm started coverage on shares of ARS Pharmaceuticals in a research report on Tuesday, November 4th. They issued a “buy” rating and a $30.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of ARS Pharmaceuticals in a research note on Wednesday, January 21st. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $30.67.

ARS Pharmaceuticals Stock Up 1.1%

SPRY stock opened at $9.34 on Wednesday. ARS Pharmaceuticals has a 1-year low of $6.66 and a 1-year high of $18.90. The business’s 50 day simple moving average is $10.45 and its 200 day simple moving average is $10.42. The company has a current ratio of 6.66, a quick ratio of 6.51 and a debt-to-equity ratio of 1.14. The firm has a market capitalization of $923.26 million, a PE ratio of -11.53 and a beta of 0.79.

Hedge Funds Weigh In On ARS Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the company. American Assets Inc. bought a new stake in ARS Pharmaceuticals during the third quarter valued at approximately $553,000. Geode Capital Management LLC raised its position in ARS Pharmaceuticals by 6.5% in the second quarter. Geode Capital Management LLC now owns 1,342,387 shares of the company’s stock worth $23,427,000 after acquiring an additional 81,910 shares during the period. Hussman Strategic Advisors Inc. purchased a new position in shares of ARS Pharmaceuticals during the 2nd quarter worth $1,832,000. Ardsley Advisory Partners LP grew its position in shares of ARS Pharmaceuticals by 46.2% during the 2nd quarter. Ardsley Advisory Partners LP now owns 475,000 shares of the company’s stock valued at $8,289,000 after acquiring an additional 150,000 shares during the period. Finally, Levin Capital Strategies L.P. grew its position in shares of ARS Pharmaceuticals by 157.6% during the 3rd quarter. Levin Capital Strategies L.P. now owns 764,294 shares of the company’s stock valued at $7,681,000 after acquiring an additional 467,647 shares during the period. Institutional investors and hedge funds own 68.16% of the company’s stock.

About ARS Pharmaceuticals

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.